HRS-6768

N/A

Report date: 2025/11/05 17:57:38
NME

Base Information

Drug NameHRS-6768
Drug Alias NameHRS-6768HRS6768
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionFibroblast activation protein alpha modulators
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTianjin Hengrui Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Hengrui Pharmaceutical Co LtdJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A